Posted by Michael Wonder on 03 Dec 2019
Regenerative medicine advanced therapy designation granted by FDA to ADP‑A2M4 for the treatment of synovial sarcoma
3 December 2019 - Will enable expedited development and review of ADP-A2M4 with the goal of commercialisation in 2022 for patients with few other treatment options.
Adaptimmune Therapeutics today announced that it has received regenerative medicine advanced therapy designation from the U.S. FDA for ADP-A2M4 for the treatment of synovial sarcoma.
Earlier this year, FDA granted orphan drug designation to ADP-A2M4 for the treatment of soft tissue sarcomas.
